Best biotech stocks to buy in 2024

Biotechnology is a crucial part of our modern lives. This page picks out some of the leading companies in the biotechnology industry and explains what makes them stand out from the competition.
By:  & 
Updated: Nov 30, 2023
eToro 10/10

77% of retail CFD accounts lose money.

Visit site

Our financial analysts have picked out the top five biotech companies that are at the top of their field. Additionally, you can find an explanation of the industry as a whole, along with the best place to find these biotech stocks.

What are the top biotech stocks to buy?

Copy link to section

The table below contains the five companies our experts have chosen. You can either find up-to-date share price data through the table or scroll down to find out more information about each.

#Stock symbolCompany nameTrade now
1RGENRegeneron Pharmaceuticals Inc.
2NVAXNovavax, Inc.
Trade NVAX

77% of retail CFD accounts lose money.

3GILDGilead Sciences
Trade GILD

77% of retail CFD accounts lose money.

4OCGNOcugen Inc.
5NBIXNeurocrine Biosciences, Inc.
List chosen by our team of analysts, updated January 2024.

For more information about each company, simply scroll down for more details such as market caps, revenue and product ranges.

1. Regeneron Pharmaceuticals Inc. (NASDAQ: RGEN)

Copy link to section

Headquartered in New York and part of both the NASDAQ 100 and S&P 500 indexes, Regeneron Pharmaceuticals is a biotech and pharmaceutical company that was founded in 1988. Regeneron generates around $8 billion of revenue per year and employs over 8,000 staff.

Its top pharmaceutical products include Aflibercept, Analyst, Praluent, Dupixent, Kevzara, Libtayo, and Inmazeb, and they are used to treat things like inflammation, blindness, arthritis, cardiovascular disease, cancer and even Ebola. With a market cap of over $50 billion, its sheer scale and the variety of treatments it offers have secured its place on our list. 

Recently, Regeneron was in the news for providing an experimental COVID-19 antibody treatment for President Trump. Its recent share price performance has been solid if a little volatile, though we can foresee growth with the introduction of new treatments.

Sign-up & trade Regeneron Pharmaceuticals Inc.

2. Novavax, Inc. (NASDAQ: NVAX)

Copy link to section

Based in Maryland, US, and founded in 1987, Novavax is a pharmaceutical company that creates experimental vaccines for major diseases. It did not have a successful launch until its 2021 NVX-CoV2373 COVID-19 vaccine, and it has now applied for emergency use in the US. It also has a phase 3 clinical trial underway for an influenza vaccine, NanoFlu. 

Given its lack of a successful launch until 2021, its share price has been extremely volatile. However, from 2020 onwards, it has experienced rapid growth and has now has a market cap in excess of $12 billion. This makes it a strong growth stock that has the potential to generate dramatic returns, though its experimental focus comes with increased risks. 

Looking to the future, a major potential catalyst comes in the form of Novavax’s COVID-19 vaccine receiving formal authorisation. Moreover, Novavax claims its vaccine has higher efficacy than some of the major COVID-19 vaccines, though this is largely down to where and how it is tested. If the company can secure approval, it could be en route to profits. 

Sign-up & trade Novavax

77% of retail CFD accounts lose money.

3. Gilead Sciences (NASDAQ: GILD)

Copy link to section

Gilead Sciences is an American company that develops treatments for a variety of life threatening diseases. It’s best known for its treatment for Hepatitis B and C, HIV, and Influenza. Like many of the companies on this list, it was created in the 1980s, and has been public since 1992.

This type of stock often ebbs and flows with the success of its treatments and Gilead is no different. It did well initially out of the pandemic, thanks to a coronavirus treatment called Veklury, that sent its stock soaring above $80 and to its highest price in five years. As other companies developed vaccines, that price began to wane again.

The big thing with any biotech company is its ability to develop new drugs. Successful ones almost guarantee profits for many years but they are difficult to find and so one route is to buy up other companies to grow into new areas. Gilead has done this to get exposure to cancer and cardiovascular medication, so that it has a robust range of treatments for serious illnesses that it can use to turn into long term profits.

Sign-up & trade Gilead Sciences

77% of retail CFD accounts lose money.

4. Ocugen Inc. (NASDAQ: OCGN)

Copy link to section

Based in Philadelphia and founded in 2013, Ocugen is a clinical-stage biopharmaceutical company that is focussed on developing treatments for rare eye diseases. 

The main reason it is on our list is because of its potential for dramatic growth. With only around 50 employees and a market cap of just over $2 billion, the company has plenty of headroom, especially considering the company had a dramatically higher valuation a few years ago.

While Ocugen currently produces virtually no revenue, investors are banking on one of its innovative treatments reaching commercialisation, though exactly when this will happen remains to be seen. Ocugen is not a stock for the faint of heart, though, for brave investors with an ambitious eye, it could be a winner. 

Sign-up & trade Ocugen Inc.

5. Neurocrine Biosciences, Inc. (NASDAQ: NBIX)

Copy link to section

Neurocrine Biosciences is an American biopharmaceutical company founded in 1992 and based in San Diego, California. The company pioneers treatments for neurological and endocrine-related diseases and disorders.

The company’s main drug, Valbenazine, was approved for use in the US for adults with Tardive Dyskinesia in 2017, and this is the main source of its nearly $800 million yearly revenue. Alongside Valbenazine, Neurocrine is developing treatments at various stages of research for Parkinson’s disease, Tourette syndrome, and congenital adrenal hyperplasia.

The fact that Neurocrine has the inherent value of a profitable treatment combined with numerous potentially lucrative clinical-stage treatments has resulted in the company being on this list. We feel it strikes a nice blend of an $8 billion value stock with plenty of growth potential, as its work with a partner to treat endometriosis and uterine fibroids demonstrates. 

Sign-up & trade Neurocrine Biosciences

Where to buy the best biotech shares

Copy link to section

Generally, the best place to find shares is through a reliable stockbroker with low fees. These are online services that allow you to easily control your entire investment portfolio from a single, user-friendly interface.

Min. Deposit
$ 10
Best offer
User Score
Up to $240 bonus!
Deposit with ACA, Wire, Pay with my bank
Invest for dividends and get payout on stocks on Ex-Dividend day
Start Trading
Payment Methods:
Bank Transfer, Credit Card, Debit Card, PayPal, Wire Transfer
Full Regulations:

77% of retail CFD accounts lose money.

Min. Deposit
$ 100
Best offer
User Score
Trade +2000 CFDs on Shares, Options, Commodities & more
Unlimited risk-free Demo Account
0 commissions & attractive spreads with up to 1:5 leverage
Start Trading
Payment Methods:
American Express, Apple Pay, Bank Transfer, Credit Card, Debit Card, Discover, Google Pay, Mastercard, PayPal, SEPA, Trustly, Visa, , skrill
Full Regulations:
ASIC, FCA, FSA, MAS, cysec-250-14-regulator, isa-regulator

Buy or sell stock CFDs with Plus500. 82% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Min. Deposit
Best offer
User Score
Diverse stock selection providing investors with a diverse array of options for their portfolios.
Advanced trading tools aiding in executing trades with precision in the dynamic stock market.
Easy portfolio management.
Start Trading
Payment Methods:
ACH, Bank Wire, Check
Full Regulations:

What is a biotech stock?

Copy link to section

A biotech stock is a publicly-traded company that harnesses biological technology. This can include cellular and biomolecular processes with the main aim of creating technologies that enhance quality of life. A simple example of biotechnology that has been used for generations is the fermentation process for certain kinds of cheese. 

Are biotech shares a good investment?

Copy link to section

Biotech stocks are high-risk, high-reward investments. Many of them are in the process of developing drugs that could eventually solve major illnesses and address multi-billion dollar markets. 

However, one misstep can have dramatic consequences. For example, if a US-based biotech company receives approval or rejection on one batch of trial data from the U.S. Food and Drug Administration, it can send a stock soaring or plummeting in a matter of minutes. 

The important thing you need to look for in biotech shares is catalyst moments. Before investing, make sure you are aware of the key dates around which a company’s success or failure will be revealed. 

While there can never be true certainty that a biotech stock will be successful, knowing the major milestones can help you anticipate market movements ahead of time. For the latest news on the biotech sector, click on one of our news links below. 

Sign up to a broker to buy biotech stocks

Latest biotech news

Copy link to section
Altimmune (NASDAQ: ALT) stock proce has staged a strong recovery in the past few days, making it one of the most popular companies among day traders. The shares jumped to a high of $8.63 on Thursday, about 306% above the lowest point this year, giving it a market cap of over $353 million. Strong obe
Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) jumped some 12% today after AbbVie Inc (NYSE: ABBV) said it will buy the drug company that focuses primarily on neurological disorders. AbbVie seems to be on a buying spree AbbVie is willing to spend about $8.7 billion to acquire the Nasdaq-listed fir
TG Therapeutics (NASDAQ: TGTX) stock price continued its recovery after the company published strong financial results. The shares jumped to the psychologically important level of $15, its highest point since April 23rd. They have soared by more than 130% from their lowest level in October. TG Thera
EyePoint Pharmaceuticals (NASDAQ: EYPT) stock price has surged hard this week as it became a favorite among StockTwits traders. The shares jumped to a high of $22.40 on Monday, its highest point since November 2019. They have now risen by over 778% from the lowest level this year, bringing the marke
Roche Holding AG Genussscheine (SWX: ROG) says it will acquire Carmot Therapeutics for $2.7 billion in cash. Its shares are up 3.0% at writing. Why is Roche buying Carmot Therapeutics? Shareholders of the biotechnology company may also receive another $400 million subject to reaching certain milesto
Penny stocks like Green Giant (GGE), Neximmune (NEXI), Altimmune (ALT), and Harbor Custom Development (HCDI) were among the best-performing companies in Wall Street on Friday. All of them jumped by more than 40% even as the Nasdaq 100 and S&P 500 indices pulled back.  These companies have n

Sources & references
Risk disclaimer
Charlie Hancox
Financial Writer
Charlie is a Financial Writer for Invezz. He covers commodities, cryptocurrencies, and breaking news. Prior to joining Invezz he helped grow Crux Investor into the fastest-growing... read more.
Jayson Derrick
Senior Editor of News
Jayson was the Lead News Editor at Invezz until 2023 overseeing the team of reporters, analysts and strategic direction of news content. He traded stocks professionally... read more.